101 results
Phase1: To characterize the safety and tolerability of isatuximab in combination with atezolizumab in participants with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and…
The main objective of this study is to test the effects of combined SGLT1 and SGLT2 inhibition with sotagliflozin on hemoconcentration and plasma volume in patients with heart failure.
The primary objective for this study is as follows:Within the TP53 wild-type populationTo compare overall survival (OS) in patients with relapsed or refractory AML who havebeen randomized to idasanutlin in combination with cytarabine versus those…
To demonstrate that ofatumumab is superior to teriflunomide in reducing the frequency of confirmed relapses as evaluated by the annualized relapse rate (ARR) in patients with relapsing MS
Earlier research nas shown the emerging efficacy and safety profile for INC424, which supports further studies in PV subjects who demonstrate resistance or intolerance to HU therapy [Barosi et al.2009]. This pivotal phase III trial (CINC424B2301) is…
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
The primary objective of the study is to ascertain the feasibility and safety to image tumor angiogenesis in head- and neck cancer patients using Ga-68-DOTA-RGD2 PET/CT. Secondary objectives are to determine the pharmacokinetics and biodistribution…
*To evaluate the safety and tolerability of RO7009789 and vanucizumab when administered in combination* To determine the maximum tolerated dose (MTD) (for the SC administration and potentially for the IV), route and recommended Phase II dose of…
MAIN OBJECTIVEDose escalation phase :- To determine the MTD and/or RDE of alpelisib (BYL719) in combination with everolimus, and the MTD and/or RDE of alpelisib in combination with everolimus and exemestaneDose expansion part:- To describe safety…
PRIMARY- Phase Ib: To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 regimen (RP2R) of ribociclib and trametinib in patients with solid tumors- Phase II: To assess overall response rate (ORR) with the combination of…
The objective of this trial is to compare standard treatment with radium-223-chloride (proven surivval benefit) with treatment with rhenium-188-HEDP, which is nowadays only used for pain palliation. This trial includes patients with metastatic…
Primary Objectives1. to establish the safety of intravenous administration of a therapeutic peptideamount of the CP042. to assess the biodistribution and dosimetry of 111In-CP04 in cancer and normal tissues and to determine critical organs.Secondary…
Part 1: Determine the Recommended Phase II Dose
Primary Objective:To assess the efficacy potential of GSK3196165 on pain in inflammatory HOA.Secondary endpoints:To evaluate impact of GSK3196165 on average and worst HOA pain, over time.To assess the impact of GSK3196165 on hand pain (on use),…
Objectives: The primary objectives of the study are to assess whether 80 mg LY2439821 every 2 weeks (Q2W) or every 4 weeks (Q4W) is:* Superior to placebo at Week 12 in the treatment of patients with moderate-to-severe plaque Ps as measured by: o…
Primary ObjectivesPart A: RO6874281 Dose Escalation as a Single AgentThe primary objectives for this study are as follows:* To describe the safety and tolerability profile of RO6874281 as a single agent* To determine the maximum tolerated dose (MTD…
The objective of the study is to evaluate the safety profile of denosumab in subjects with Giant Cell Tumor of bone.
The primary objective of the trial is to evaluate the risk versus benefit of denosumab in maintenance setting in patients requiring long-use (>1 year) of denosumab. For that purpose, the treatment schedule with reduced dose density (120mg SC…
Primary Objective * To evaluate the effect of a 6-week treatment with elafibranor versus placebo on hepatic lipid composition in subjects with a fatty liver.Secondary objectives * To evaluate the between treatment difference (elafibranor 120 mg/d vs…
The primary objective of the entire study is to compare rogaratinib (BAY1163877) with chemotherapy (docetaxel, paclitaxel or vinflunine) in terms of prolonging the Overall survival (OS) of patients with FGFR positive urothelial carcinoma.